Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen
Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen
复制标题
DOI：
10.1126/science.284.5418.1351
复制
发表时间：
1999-05-21
期刊：
影响因子：
56.9
通讯作者：
Rosenberg, SA
中科院分区：
文献类型：
--
作者：
Wang, RF;Wang, X;Rosenberg, SA
为了鉴定 CD4(+) T 细胞识别的肿瘤特异性抗原，开发了一种方法，可以在表达主要组织相容性复合物 (MHC) II 类加工和呈递途径的基本成分的基因工程细胞系中筛选不变链互补 DNA 融合文库。这导致了人类CDC27突变形式的鉴定，它产生了HLA-DR4限制性黑色素瘤抗原。通过生化方法分离的磷酸丙糖异构酶的突变形式也被鉴定为HLA-DR1限制性抗原。因此，这种方法可能普遍适用于鉴定CD4(+) T细胞识别的抗原，这有助于制定治疗癌症、自身免疫性疾病或传染病患者的策略。
In an effort to identify tumor-specific antigens recognized by CD4(+) T cells, an approach was developed that allows the screening of an invariant chain-complementary DNA fusion library in a genetically engineered cell line expressing the essential components of the major histocompatibility complex (MHC) class II processing and presentation pathway. This Led to the identification of a mutated form of human CDC27, which gave rise to an HLA-DR4-restricted melanoma antigen, A mutated form of triosephosphate isomerase, isolated by a biochemical method, was also identified as an HLA-DR1-restricted antigen. Thus, this approach may be generally applicable to the identification of antigens recognized by CD4(+) T cells, which could aid the development of strategies for the treatment of patients with cancer, autoimmune diseases, or infectious diseases.